Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-Dose vs Standard-Dose Quadrivalent Influenza Vaccine in Adults 65–79 Years in Galicia
2023-506977-36-00Phase 4Authorised
- Sponsor
- Complejo Hospitalario Universitario de Santiago
- Start
- Sep 2023
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial in influenza, pneumonia and Cardiovascular disease (CVD) comparing High-dose QIV (Efluelda) with Standard-dose QIV (Influvac Tetra) (2 arms). Primary endpoint: Hospitalization due to influenza or pneumonia. Planned start Sep 2023; status: authorised.
02
Drugs
influenza vaccine (quadrivalent, high-dose)Influenza A virus A/Texas/50/2012 X-223A (H3N2) hemagglutinin antigen
03
Conditions
influenzapneumoniaCardiovascular disease (CVD)
Beyond the preview
Go deeper on 2023-506977-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506977-36-00.